全文获取类型
收费全文 | 11549篇 |
免费 | 2860篇 |
国内免费 | 242篇 |
专业分类
耳鼻咽喉 | 659篇 |
儿科学 | 296篇 |
妇产科学 | 234篇 |
基础医学 | 358篇 |
口腔科学 | 327篇 |
临床医学 | 1780篇 |
内科学 | 2678篇 |
皮肤病学 | 529篇 |
神经病学 | 1452篇 |
特种医学 | 535篇 |
外科学 | 3137篇 |
综合类 | 60篇 |
现状与发展 | 2篇 |
一般理论 | 2篇 |
预防医学 | 919篇 |
眼科学 | 362篇 |
药学 | 196篇 |
中国医学 | 1篇 |
肿瘤学 | 1124篇 |
出版年
2024年 | 96篇 |
2023年 | 513篇 |
2022年 | 146篇 |
2021年 | 303篇 |
2020年 | 738篇 |
2019年 | 220篇 |
2018年 | 663篇 |
2017年 | 630篇 |
2016年 | 788篇 |
2015年 | 709篇 |
2014年 | 961篇 |
2013年 | 1081篇 |
2012年 | 379篇 |
2011年 | 301篇 |
2010年 | 659篇 |
2009年 | 880篇 |
2008年 | 351篇 |
2007年 | 232篇 |
2006年 | 332篇 |
2005年 | 218篇 |
2004年 | 166篇 |
2003年 | 139篇 |
2002年 | 121篇 |
2001年 | 217篇 |
2000年 | 147篇 |
1999年 | 209篇 |
1998年 | 271篇 |
1997年 | 280篇 |
1996年 | 329篇 |
1995年 | 295篇 |
1994年 | 183篇 |
1993年 | 139篇 |
1992年 | 162篇 |
1991年 | 165篇 |
1990年 | 93篇 |
1989年 | 156篇 |
1988年 | 131篇 |
1987年 | 97篇 |
1986年 | 113篇 |
1985年 | 110篇 |
1984年 | 98篇 |
1983年 | 81篇 |
1982年 | 89篇 |
1981年 | 58篇 |
1980年 | 76篇 |
1979年 | 40篇 |
1978年 | 54篇 |
1977年 | 49篇 |
1975年 | 48篇 |
1972年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Cross‐sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease 下载免费PDF全文
993.
The Effects of Mechanical and Thermal Stimuli on Local Field Potentials and Single Unit Activity in Parkinson's Disease Patients 下载免费PDF全文
994.
Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management 下载免费PDF全文
995.
Alan E. O'Connor MB DCH Jeremy T. Parry MB Drew B. Richardson MB BSc Sanjiv Jain MB BS Peter B. Herdson MB 《Academic emergency medicine》2002,9(9):957-959
OBJECTIVES: In spite of advances in medical technology, there remains a high discrepancy rate between the antemortem clinical diagnosis and postmortem examination diagnosis for patients who die in hospitals. The aim of this study was to compare the clinical and postmortem examination diagnoses of patients who died in the emergency department (ED) of a tertiary hospital, and to analyze any discrepancy between them. METHODS: The study was a retrospective chart review of patients who died in the ED of a tertiary referral teaching hospital and a comparison of the antemortem diagnosis with the autopsy diagnosis. Any missed diagnosis was classified, according to the Goldman criteria, into major and minor missed diagnoses. RESULTS: A total of 59 patients were eligible for inclusion in the study. There was complete agreement between the antemortem diagnosis and the autopsy result in 51% of cases. The incidence of major missed diagnoses-where if the diagnosis had been known before the patient died, treatment may have been altered or survival may have been prolonged-was 7%. CONCLUSIONS: There is a significant discrepancy rate between the antemortem diagnosis and the autopsy diagnosis. However, in this study, serious missed diagnoses in which outcome may have been significantly altered are unusual among those who die in the ED of a tertiary referral hospital. 相似文献
996.
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer 下载免费PDF全文
Israel Pena MD Gary L. Clayman MD Elizabeth G. Grubbs MD Jeffrey M. Bergeron BS Jr Steven G. Waguespack MD Maria E. Cabanillas MD Ramona Dadu MD Mimi I. Hu MD Bryan M. Fellman MS Yisheng Li PhD Neil D. Gross MD Stephen Y. Lai MD PhD Erich M. Sturgis MD Mark E. Zafereo MD 《Head & neck》2018,40(1):79-85
997.
998.
A five‐CpG DNA methylation score to predict metastatic‐lethal outcomes in men treated with radical prostatectomy for localized prostate cancer 下载免费PDF全文
Milan S. Geybels PhD Andrew S. McDaniel MD PhD Ming Yu PhD Suzanne Kolb MPH Hong Zong MD Kelly Carter BS Javed Siddiqui MS Anqi Cheng MS Jonathan L. Wright MD MPH Colin C. Pritchard MD PhD Raymond Lance MD Dean Troyer MD Jian‐Bing Fan PhD Elaine A. Ostrander PhD James Y. Dai PhD Scott A. Tomlins MD PhD Janet L. Stanford PhD MPH 《The Prostate》2018,78(14):1084-1091
Background
Prognostic biomarkers for localized prostate cancer (PCa) could improve personalized medicine. Our group previously identified a panel of differentially methylated CpGs in primary tumor tissue that predict disease aggressiveness, and here we further validate these biomarkers.Methods
Pyrosequencing was used to assess CpG methylation of eight biomarkers previously identified using the HumanMethylation450 array; CpGs with strongly correlated (r >0.70) results were considered technically validated. Logistic regression incorporating the validated CpGs and Gleason sum was used to define and lock a final model to stratify men with metastatic‐lethal versus non‐recurrent PCa in a training dataset. Coefficients from the final model were then used to construct a DNA methylation score, which was evaluated by logistic regression and Receiver Operating Characteristic (ROC) curve analyses in an independent testing dataset.Results
Five CpGs were technically validated and all were retained (P < 0.05) in the final model. The 5‐CpG and Gleason sum coefficients were used to calculate a methylation score, which was higher in men with metastatic‐lethal progression (P = 6.8 × 10?6) in the testing dataset. For each unit increase in the score there was a four‐fold increase in risk of metastatic‐lethal events (odds ratio, OR = 4.0, 95%CI = 1.8–14.3). At 95% specificity, sensitivity was 74% for the score compared to 53% for Gleason sum alone. The score demonstrated better prediction performance (AUC = 0.91; pAUC = 0.037) compared to Gleason sum alone (AUC = 0.87; pAUC = 0.025).Conclusions
The DNA methylation score improved upon Gleason sum for predicting metastatic‐lethal progression and holds promise for risk stratification of men with aggressive tumors. This prognostic score warrants further evaluation as a tool for improving patient outcomes.999.
Nateglinide is an oral antidiabetic medication (OAD) that acts through rapid, short-term stimulation of insulin production. This study was conducted to identify the nature of any adverse effects associated with nateglinide and to evaluate its clinical efficacy in patients with type 2 diabetes, with particular attention to hypoglycemia. Patients with type 2 diabetes who were OAD naïve (n=547), whose fasting blood glucose levels were 150 mg/dL or lower, and who had started to take nateglinide alone were recruited from 139 centers in Japan with a 12-week observation period. The incidence of adverse reactions was 7.62%. Hypoglycemia accompanied by hypoglycemic symptoms was the most prevalent adverse event (2.10%; 11/525). Nine of 11 episodes required no therapeutic intervention. Severe hypoglycemia was recognized in only 1 case of diabetes complicated by serious renal dysfunction, for which nateglinide has been contraindicated in Japan. No subject experienced symptoms of nocturnal or prolonged hypoglycemia. After 12 weeks of nateglinide treatment, decreases were noted in hemoglobin A1c (0.82%), postprandial glucose (reduced by 59.4 mg/dL to 158.0 mg/dL), and fasting glucose (reduced by 11.7 mg/dL to 122.4 mg/dL). Nateglinide, which demonstrates limited risk of hypoglycemia and effectively controls blood glucose level, is regarded as a useful drug for the treatment of patients with type 2 diabetes. 相似文献
1000.
RC Cook MBChB J Zachariah MB BS F Cree BSc HE Harrison PhD 《International journal of clinical practice》1996,50(3):125-128
SUMMARY A new amoxycillin/clavulanate regimen (‘Augmentin-Duo’ 400/57), to be given orally in two divided doses, has been proposed to overcome the inconvenience of tid dosing. This observer-blind, multicentre study randomised children aged two to 12 years with lower respiratory tract infection to seven days' treatment with either amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day (221 patients) or the currently prescribed amoxycillin/clavulanate regimen of 20/5mg/kg/day tid (216 patients). Clinical success (cure) rates at follow up were 81.0% for the bid group and 77.8% for the tid group [difference 3.2%; 95% CI (-4.36, 10.80)], indicating that the regimens were of equivalent efficacy. Both regimens were well tolerated, and there was no statistically significant difference in the incidence of adverse experiences between the two groups. Compliance with study medication was high and similar for both groups (80% compliance: bid 90.0%; tid 87.0%). 相似文献